POP Biotechnologies (POP BIO), a
Data from this clinical study has been published today in BMC Medicine (https://doi.org/10.1186/s12916-022-02661-1).
EuCorVac-19 is an RBD-based vaccine consisting of POP BIO's Spontaneous Nanoliposome Antigen Particle (SNAP) technology in combination with the adjuvant genetically modified E. coli Monophosphoryl Lipid A (EcML), produced by EuCorVac-19 manufacturer
In this Phase II clinical study, 229 participants were enrolled at five clinical sites in
RBD correlated with antibodies against the Spike and with virus neutralization.
The published data shows that in this trial,EuCorVac-19 was well-tolerated and induced antibodies in a dose-dependent manner that neutralizes SARS-CoV-2. The unique liposome display approach of EuCorVac-19, which lacks any immunogenic protein components besides the antigen itself, coupled with the lack of increased adverse events during boosting suggests the vaccine platform is amenable to multiple boosting regimes in the future to help control the ongoing COVID-19 pandemic.
The results of this Phase II trial provide critical evidence of the value of the SNAP platform. This data provides invaluable support towards our platform's development, further enabling the creation of new vaccines with the potential to alleviate suffering worldwide,' says POP BIO co-founder
The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases.' says company co-founder and study co-author
Presently, EuCorVac-19 is undergoing two Phase III clinical studies in simultaneous studies in
POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.
POP Biotechnologies (POP BIO): POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from
POP BIO's SNAP Technology: POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and other diseases through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle-formation and liposome display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.
About
About
(C) 2022 Electronic News Publishing, source